The future of surgical management of inflammatory bowel disease

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

IBD is a complex genetic disorder that will be treated using medical and surgical therapies that are specifically tailored for the individual patient using patient defined genetic and metabolic determinants of disease. The disease's pathophysiologic complexity will defy the rapid discovery of a simple, all encompassing cure. These patient defined genetic and metabolic factors will help determine the type and timing of surgery, its prognosis, and risk. The malignant risk of IBD will be more accurately defined and the timing of surgery determined using tests other than colonoscopy. Continued improvements in minimally invasive techniques of surgery will offer the IBD patient rapid relief of complications of disease with the least disability and stress. Fundamentally, the paradigm of care for the future will require the recognition that both surgical and medical therapies will need to be chosen in concert with the purpose of providing the best therapy for that individual patient at that point in their disease history in order to maximize response while minimizing long-term recurrence.

Original languageEnglish (US)
Pages (from-to)813-817
Number of pages5
JournalDiseases of the Colon and Rectum
Volume51
Issue number6
DOIs
StatePublished - Jun 1 2008

Fingerprint

Inflammatory Bowel Diseases
Inborn Genetic Diseases
Minimally Invasive Surgical Procedures
Metabolic Diseases
Colonoscopy
Therapeutics
Recurrence

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

@article{fb28c1de279849f6b1702e9a18759718,
title = "The future of surgical management of inflammatory bowel disease",
abstract = "IBD is a complex genetic disorder that will be treated using medical and surgical therapies that are specifically tailored for the individual patient using patient defined genetic and metabolic determinants of disease. The disease's pathophysiologic complexity will defy the rapid discovery of a simple, all encompassing cure. These patient defined genetic and metabolic factors will help determine the type and timing of surgery, its prognosis, and risk. The malignant risk of IBD will be more accurately defined and the timing of surgery determined using tests other than colonoscopy. Continued improvements in minimally invasive techniques of surgery will offer the IBD patient rapid relief of complications of disease with the least disability and stress. Fundamentally, the paradigm of care for the future will require the recognition that both surgical and medical therapies will need to be chosen in concert with the purpose of providing the best therapy for that individual patient at that point in their disease history in order to maximize response while minimizing long-term recurrence.",
author = "Walter Koltun",
year = "2008",
month = "6",
day = "1",
doi = "10.1007/s10350-008-9266-8",
language = "English (US)",
volume = "51",
pages = "813--817",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

The future of surgical management of inflammatory bowel disease. / Koltun, Walter.

In: Diseases of the Colon and Rectum, Vol. 51, No. 6, 01.06.2008, p. 813-817.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The future of surgical management of inflammatory bowel disease

AU - Koltun, Walter

PY - 2008/6/1

Y1 - 2008/6/1

N2 - IBD is a complex genetic disorder that will be treated using medical and surgical therapies that are specifically tailored for the individual patient using patient defined genetic and metabolic determinants of disease. The disease's pathophysiologic complexity will defy the rapid discovery of a simple, all encompassing cure. These patient defined genetic and metabolic factors will help determine the type and timing of surgery, its prognosis, and risk. The malignant risk of IBD will be more accurately defined and the timing of surgery determined using tests other than colonoscopy. Continued improvements in minimally invasive techniques of surgery will offer the IBD patient rapid relief of complications of disease with the least disability and stress. Fundamentally, the paradigm of care for the future will require the recognition that both surgical and medical therapies will need to be chosen in concert with the purpose of providing the best therapy for that individual patient at that point in their disease history in order to maximize response while minimizing long-term recurrence.

AB - IBD is a complex genetic disorder that will be treated using medical and surgical therapies that are specifically tailored for the individual patient using patient defined genetic and metabolic determinants of disease. The disease's pathophysiologic complexity will defy the rapid discovery of a simple, all encompassing cure. These patient defined genetic and metabolic factors will help determine the type and timing of surgery, its prognosis, and risk. The malignant risk of IBD will be more accurately defined and the timing of surgery determined using tests other than colonoscopy. Continued improvements in minimally invasive techniques of surgery will offer the IBD patient rapid relief of complications of disease with the least disability and stress. Fundamentally, the paradigm of care for the future will require the recognition that both surgical and medical therapies will need to be chosen in concert with the purpose of providing the best therapy for that individual patient at that point in their disease history in order to maximize response while minimizing long-term recurrence.

UR - http://www.scopus.com/inward/record.url?scp=44749087317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44749087317&partnerID=8YFLogxK

U2 - 10.1007/s10350-008-9266-8

DO - 10.1007/s10350-008-9266-8

M3 - Review article

VL - 51

SP - 813

EP - 817

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 6

ER -